BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1716696)

  • 1. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
    Russell KJ; Dunatov C; Hafermann MD; Griffeth JT; Polissar L; Pelton J; Cole SB; Taylor EW; Wiens LW; Koh WJ
    J Urol; 1991 Oct; 146(4):1046-52. PubMed ID: 1716696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992.
    Schneider SB; Schweitzer VG; Parker RG; Bycott PW
    Am J Clin Oncol; 1996 Feb; 19(1):65-72. PubMed ID: 8554039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
    Chauvet B; FĂ©lix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
    J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
    Zagars GK
    J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
    Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
    Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
    Ritter MA; Messing EM; Shanahan TG; Potts S; Chappell RJ; Kinsella TJ
    J Clin Oncol; 1992 Aug; 10(8):1208-17. PubMed ID: 1378886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
    Zagars GK; Sherman NE; Babaian RJ
    Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.
    Green GA; Hanlon AL; Al-Saleem T; Hanks GE
    Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
    Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
    J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
    BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.